Maxigen Biotech Inc. (TPE:1783)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
42.40
+0.90 (2.17%)
Mar 10, 2026, 9:39 AM CST
-15.54%
Market Cap 3.35B
Revenue (ttm) 792.49M
Net Income (ttm) 234.07M
Shares Out 80.69M
EPS (ttm) 2.59
PE Ratio 16.02
Forward PE n/a
Dividend 0.83 (1.93%)
Ex-Dividend Date Sep 5, 2025
Volume 19,159
Average Volume 96,990
Open 41.80
Previous Close 41.50
Day's Range 41.80 - 42.45
52-Week Range 35.55 - 50.70
Beta 0.29
RSI 29.88
Earnings Date Mar 20, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic vis... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1783
Full Company Profile

Financial Performance

In 2024, Maxigen Biotech's revenue was 680.65 million, an increase of 9.41% compared to the previous year's 622.12 million. Earnings were 190.17 million, an increase of 14.68%.

Financial Statements

News

There is no news available yet.